Prognostic stratification in MDS/MPN syndromes other than CMML: an Italian multicenter real-world study

Abstract MDS/MPN syndromes comprise a heterogeneous group of myeloid neoplasms. While CMML has been extensively characterized, data on other MDS/MPN entities remain limited, particularly in real-world settings. We conducted a nationwide, multicenter retrospective study including adult patients with MDS/MPN syndromes other than CMML from 17 Italian centers. Patients were classified as MDS/MPN with SF3B1 mutation and thrombocytosis ( SF3B1 -T), atypical chronic myeloid leukemia/chronic neutrophilic leukemia (aCML/CNL), or MDS/MPN not otherwise specified (NOS). A total of 101 patients were included (median age 71 years). MDS/MPN SF3B1 -T showed a significant survival advantage compared with MDS/MPN NOS and aCML/CNL (OS p = 0.0058, LFS p = 0.012). aCML/CNL displayed the worst outcomes and most genetic complexity. Across the overall cohort, IPSS-M demonstrated the highest discriminative ability and calibration accuracy for both OS and LFS, outperforming CMML-directed models, including BLAST-clinical and BLAST-molecular whereas disease-specific scores provided optimal stratification within individual entities but failed to adequately predict outcomes in MDS/MPN NOS. In this real-world analysis, IPSS-M emerged as the most robust prognostic framework across MDS/MPN entities other than CMML. The inability of current tools to reliably stratify patients with MDS/MPN NOS underscores the biological heterogeneity of this category and highlights the urgent need for integrated clinical and genomic prognostic models.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Medicine
Published
2026-09-01
DOI
https://doi.org/10.1007/s10238-026-02287-0
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Prognostic stratification in MDS/MPN syndromes other than CMML: an Italian multicenter real-world study

Luca Guarnera, Michelina Santopietro, Francesco Muriano, Roberto Latagliata et al.
Clinical and Experimental Medicine
Acute Myeloid Leukemia Research
article

Prognostic stratification in MDS/MPN syndromes other than CMML: an Italian multicenter real-world study

Luca Guarnera, Michelina Santopietro, Francesco Muriano, Roberto Latagliata, Paola Guglielmelli, Luca Maurillo, Lorenzo Rizzo, Caterina Tatarelli, Mara Memoli, Alessandro M. Vannucchi, Ambra Di Veroli, Giovanni Iaquinta, Antonio Spadea, Maria Teresa Voso, Federica Catania, Paola Grammatico, Anna Lina Piccioni, Sabrina Leonetti Crescenzi, Costanza Andriola, Francesca Romana Iovene, Sabrina Mariani, Giuseppe Gaetano Loscocco, Prassede Salutari, Katia Paciaroni, Emilia Scalzulli, Alessandro Andriani, Adriano Venditti, Marta Riva, Massimo Breccia, Emiliano Fabiani, Gianluca Albanese, Bruno Fattizzo, Annalisa Biagi, Novella Pugliese, Alfredo Molteni
article en

Abstract

Abstract MDS/MPN syndromes comprise a heterogeneous group of myeloid neoplasms. While CMML has been extensively characterized, data on other MDS/MPN entities remain limited, particularly in real-world settings. We conducted a nationwide, multicenter retrospective study including adult patients with MDS/MPN syndromes other than CMML from 17 Italian centers. Patients were classified as MDS/MPN with SF3B1 mutation and thrombocytosis ( SF3B1 -T), atypical chronic myeloid leukemia/chronic neutrophilic leukemia (aCML/CNL), or MDS/MPN not otherwise specified (NOS). A total of 101 patients were included (median age 71 years). MDS/MPN SF3B1 -T showed a significant survival advantage compared with MDS/MPN NOS and aCML/CNL (OS p = 0.0058, LFS p = 0.012). aCML/CNL displayed the worst outcomes and most genetic complexity. Across the overall cohort, IPSS-M demonstrated the highest discriminative ability and calibration accuracy for both OS and LFS, outperforming CMML-directed models, including BLAST-clinical and BLAST-molecular whereas disease-specific scores provided optimal stratification within individual entities but failed to adequately predict outcomes in MDS/MPN NOS. In this real-world analysis, IPSS-M emerged as the most robust prognostic framework across MDS/MPN entities other than CMML. The inability of current tools to reliably stratify patients with MDS/MPN NOS underscores the biological heterogeneity of this category and highlights the urgent need for integrated clinical and genomic prognostic models.

Clinical and Experimental Medicine
University of Rome Tor Vergata (IT), Università Campus Bio-Medico (IT), University of Milan (IT), Azienda Ospedaliera San Giovanni Addolorata (IT), Policlinico Umberto I (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), ASL Roma (IT), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Saint Camillus International University of Health and Medical Sciences (IT), Federico II University Hospital (IT), Azienda Ospedaliera Sant'Andrea (IT), Ospedale di Belcolle (IT), Villa Pineta Hospital (IT), Ospedale Santa Maria Goretti (IT), Azienda USL di Pescara (IT), Carlo Forlanini Hospital (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Azienda Sanitaria Locale Roma 3 (IT), Villa Torri Hospital (IT), Istituti Ospitalieri di Cremona (IT), Azienda Socio Sanitaria Territoriale di Cremona, University of Florence (IT), European Institute of Oncology (IT)
Università degli Studi di Roma Tor Vergata
Reduced inequalities
Openalex Percentile: Top 11%
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.